GET DAILY SIGNALSWhat Vaxcyte (PCVX) Earnings Could Reveal About Pipeline Progress
Key Takeaways
- Vaxcyte is expected to report third-quarter 2026 results after the market closes on Tuesday, November 3, 2026, with a conference call scheduled for November 4.
- Analysts are modeling a net loss of roughly $2.11 to $2.13 per share (EPS), compared with a $1.56 per-share loss in the same period a year ago.
- Consensus revenue expectations sit near $12.5 million, though Vaxcyte remains a clinical-stage vaccine developer with no approved product revenue.
- The quarter is largely a prelude to the company's biggest near-term catalyst: topline data from the OPUS-1 Phase 3 trial of VAX-31, expected in the fourth quarter of 2026.
- Investors will focus on cash burn, research and development (R&D) spending, and any updates to the VAX-31 clinical timeline.
- For more detail on this ticker, visit Tickeron's pages for Major News, Today's Price Move, Price Targets, and Forecast.
- To discover AI-driven trading strategies and market ideas, explore Trending AI Robots.
Why This Report Matters for a Clinical-Stage Company
Vaxcyte is a clinical-stage vaccine company, so its quarterly updates matter less for top-line revenue and more for pipeline health and balance-sheet strength. The firm is advancing VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, through Phase 3. With no commercial products yet, losses are expected to widen as trial and manufacturing costs rise. In my view, this report serves as a checkpoint on spending discipline, cash runway, and whether the company stays on track for a potentially pivotal data readout that could reshape its valuation. I also checked this using Tickeron’s AI Screener to compare sector peers.
What Analysts Are Modeling for the Quarter
Consensus estimates call for a third-quarter net loss of approximately $2.11 to $2.13 per share, wider than the $1.56 loss reported in the prior-year period. Revenue is expected around $12.5 million, reflecting collaboration or other non-product income rather than commercial sales. In the most recent quarter, Vaxcyte posted a $1.97 per-share loss, narrowly beating the $2.06 consensus, while the first quarter of 2026 brought a $2.30 loss that missed estimates. The widening losses reflect sharply higher R&D expenses tied to VAX-31 manufacturing and Phase 3 trial activity. As of June 30, 2026, the company held about $2.51 billion in cash, cash equivalents, and investments, providing a substantial runway. From what I see, this cash position remains a key buffer heading into the data readout.
How the Market Is Approaching the Release
Heading into the report, sentiment is shaped less by the headline loss and more by pipeline execution. Wall Street coverage skews positive, with a "Moderate Buy" consensus and an average price target well above recent trading levels. Vaxcyte's stock has a higher beta than the broader market, reflecting outsized sensitivity to clinical news. Historical reactions have been mixed: shares have moved on trial updates more than on the size of quarterly losses. Key risk factors this quarter include any slippage in the OPUS-1 data timeline, unexpected increases in trial or manufacturing costs, and broader sentiment shifts across the biotechnology sector. One thing that stands out is how clinical milestones continue to drive volatility more than earnings beats or misses.
Looking Ahead to the Main Catalysts
The dominant catalyst investors are watching is the topline safety, tolerability, and immunogenicity data from the OPUS-1 Phase 3 pivotal trial of VAX-31, which the company has guided to the fourth quarter of 2026. OPUS-1 compares VAX-31 directly against currently approved pneumococcal vaccines in adults, so the readout could be a significant valuation event. Beyond OPUS-1, investors should monitor results from the OPUS-2 and OPUS-3 trials, expected in the first half of 2027, as well as topline data from the VAX-31 infant Phase 2 dose-finding study. The company is also advancing VAX-A1, a vaccine candidate targeting Group A Streptococcus, where a Phase 1 study in adults has begun. On the financial side, R&D spending is likely to remain elevated as Vaxcyte builds out commercial manufacturing capacity with partners and scales its domestic fill-finish operations. Cash burn, balance-sheet strength, and any commentary on funding needs will be important signals. Because the company remains pre-revenue, the investment case hinges on clinical success rather than near-term profitability. I’m watching this closely as the data approaches.
Using AI Tools in My Research Process
When evaluating names like this, I often turn to Tickeron’s AI Daily Buy/Sell Signals to see how technical patterns align with upcoming events. It helps surface context that pure fundamentals might miss and keeps my watchlist focused on high-conviction ideas without adding extra steps to the workflow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PCVX in downward trend: price may drop because broke its higher Bollinger Band on October 05, 2026
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 44 similar instances where the stock broke above the upper band. In 37 of the 44 cases the stock fell afterwards. This puts the odds of success at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 23 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCVX as a result. In 61 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for PCVX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 30 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
PCVX moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 65 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 223 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.281) is normal, around the industry mean (3.104). P/E Ratio (-7.970) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology
Advertisement